Salarius Pharmaceuticals Stock Performance
| SLRX Stock | USD 0.96 0.01 1.05% |
The entity has a beta of 2.87, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Salarius Pharmaceuticals will likely underperform. Please check Salarius Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Salarius Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Salarius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly weak basic indicators, Salarius Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:8 | Dividend Date 2019-07-22 | Last Split Date 2024-06-17 |
1 | Shareholder Alert Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders | 01/13/2025 |
2 | Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 12 Clinical Trial Using Seclidemstat with Azacitidine to Treat H... | 02/03/2025 |
3 | SLRX stock touches 52-week low at 1.22 amid market challenges - Investing.com | 02/25/2025 |
4 | Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update | 03/24/2025 |
| Begin Period Cash Flow | 5.9 M |
Salarius |
Salarius Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 166.00 in Salarius Pharmaceuticals on December 25, 2024 and sell it today you would lose (70.00) from holding Salarius Pharmaceuticals or give up 42.17% of portfolio value over 90 days. Salarius Pharmaceuticals is currently generating 0.2236% in daily expected returns and assumes 19.3119% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Salarius, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Salarius Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Salarius Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Salarius Pharmaceuticals, and traders can use it to determine the average amount a Salarius Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0116
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.31 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Salarius Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Salarius Pharmaceuticals by adding Salarius Pharmaceuticals to a well-diversified portfolio.
Salarius Pharmaceuticals Fundamentals Growth
Salarius Stock prices reflect investors' perceptions of the future prospects and financial health of Salarius Pharmaceuticals, and Salarius Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Salarius Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (552.23 K) | ||||
| Shares Outstanding | 1.73 M | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 18.12 X | ||||
| Gross Profit | (15.84 M) | ||||
| EBITDA | (5.21 M) | ||||
| Net Income | (5.58 M) | ||||
| Cash And Equivalents | 22.65 M | ||||
| Cash Per Share | 10.09 X | ||||
| Total Debt | 221.87 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (4.53 M) | ||||
| Earnings Per Share | (5.79) X | ||||
| Market Capitalization | 1.66 M | ||||
| Total Asset | 3.02 M | ||||
| Retained Earnings | (81.92 M) | ||||
| Working Capital | 5.22 M | ||||
| Current Liabilities | 1.97 M | ||||
About Salarius Pharmaceuticals Performance
Evaluating Salarius Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Salarius Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Salarius Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -101.2 K | -96.2 K | |
| Return On Tangible Assets | (1.84) | (1.94) | |
| Return On Assets | (1.84) | (1.94) | |
| Return On Equity | (3.69) | (3.50) |
Things to note about Salarius Pharmaceuticals performance evaluation
Checking the ongoing alerts about Salarius Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Salarius Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Salarius Pharmaceuticals had very high historical volatility over the last 90 days | |
| Salarius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Salarius Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.58 M) with loss before overhead, payroll, taxes, and interest of (15.84 M). | |
| Salarius Pharmaceuticals currently holds about 22.65 M in cash with (4.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Salarius Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update |
- Analyzing Salarius Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Salarius Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Salarius Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Salarius Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Salarius Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Salarius Pharmaceuticals' stock. These opinions can provide insight into Salarius Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.